Aurobindo Pharma Arm CuraTeQ Receives UK Approval For Dyrupeg Drug
The drug Dyrupeg is used to help cancer patients with neutropenia, which is a low level of a type of white blood cell.
Aurobindo Pharma Ltd.'s wholly owned subsidiary, CuraTeQ Biologics, received approval for biosimilar Dyrupeg from the United Kingdom's Medicines and Healthcare Products Regulatory Agency, as per an exchange filing on Tuesday.
Dyrupeg is used to help cancer patients with neutropenia, which is a low level of a type of white blood cell. Earlier in April, the filing stated that Dyrupeg had received marketing authorisation in the European Union from the European Commission.
This is CuraTeQ’s third biosimilar to be approved by the agency after the approval of Bevqolva in December 2024 and Zefylti in May 2025, as per the filing.
Recently, Vaibhav Vidwani, an equity research analyst at Bonanza Portfolio, had suggested to to enter Aurobindo Pharma. The stock shows strong potential and the ability to perform well in the long run, he stated.
The company's fourth-quarter profit stayed almost flat in the fourth quarter of financial year 2024-25, thereby missing analysts' estimates.
The Hyderabad-based bulk and generic drugmaker posted a profit of Rs 903.5 crore in the quarter ended March 31, 2025, according to a disclosure to the stock exchanges. That compares with the Rs 1,013-crore consensus estimate of analysts tracked by Bloomberg.
Shares of the pharmaceutical brand closed 0.25% higher at Rs 1,104.20 apiece, nearly at par with a 0.29% advance in the benchmark NSE Nifty 50.
